Could a common diabetes pill boost Teplizumab's effects in early type 1 diabetes?

NCT ID NCT06338553

Recruiting now Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether adding a GLP-1 drug (semaglutide, sold as Rybelsus®) to the standard teplizumab treatment can help control blood sugar and improve blood vessel function in people with early stage type 1 diabetes. Researchers will give 24 participants a liquid meal test with and without the drug, measuring blood sugar, insulin, and artery health. The goal is to see if this combination can better manage the disease and reduce heart risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Rybelsus®)
What this could lead to: If it works, this could point toward a way to better manage blood sugar and protect blood vessels in people with early type 1 diabetes who are already receiving teplizumab.
What could go wrong: This is a very small, early-phase pilot study with only 24 participants. It is designed to test short-term effects, not long-term outcomes, and may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.